Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 809-817

  Wardrop, Douglas ^a,b   Steensma, David P ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anaemia; Disease classification; JAK2; Ring sideroblasts; Thrombocytosis

Indexed keywords

HYDROXYUREA; IMATINIB; JANUS KINASE 2; THROMBOPOIETIN RECEPTOR;

GENE MUTATION; HUMAN; MYELODYSPLASTIC SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS;

ANEMIA, REFRACTORY; DIAGNOSIS, DIFFERENTIAL; HUMANS; JANUS KINASE 2; MUTATION; THROMBOCYTHEMIA, ESSENTIAL; THROMBOPOIETIN; WORLD HEALTH ORGANIZATION;

EID: 60649113553     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07526.x     Document Type: Review

References (70)

1. Alcindor, T. Bridges, K.R. (2002) Sideroblastic anaemias. British Journal of Haematology, 116, 733 743.
2. Bain, B.J. (1999) The relationship between the myelodysplastic syndromes and the myeloproliferative disorders. Leukemia & Lymphoma, 34, 443 449.
3. Bain, B. (2006) Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease in older adults. British Journal of Haematology, 134, 340 author reply 340-341.
4. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189 199.
5. Bjorkman, S.E. (1956) Chronic refractory anaemia with sideroblastic bone marrow; a study of four cases. Blood, 11, 250 259.
6. Boissinot, M., Garand, R., Hamidou, M. Hermouet, S. (2006) The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anaemia with ring sideroblasts (RARS). Blood, 108, 1781 1782.
7. Bowker, G.C. Star, S.L. (2000) Sorting Things Out: Classification and Its Consequences. The MIT Press, Cambridge, MA.
8. Briere, J.B. (2007) Essential thrombocythemia. Orphanet Journal of Rare Diseases, 2, 3.
9. Cabello, A.I., Collado, R., Ruiz, M.A., Martinez, J., Navarro, I., Ferrer, R., Sosa, A.M. Carbonell, F. (2005) A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Leukemia Research, 29, 365 370.
10. Campbell, P.J., Scott, L.M., Buck, G., Wheatley, K., East, C.L., Marsden, J.T., Duffy, A., Boyd, E.M., Bench, A.J., Scott, M.A., Vassiliou, G.S., Milligan, D.W., Smith, S.R., Erber, W.N., Bareford, D., Wilkins, B.S., Reilly, J.T., Harrison, C.N. Green, A.R. (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet, 366, 1945 1953.
11. Cannizzo, E., Carulli, G., Azzara, A., Galimberti, S., Zucca, A. Petrini, M. (2008) JAK-2V617F mutation in RARS-t: a target for Imatinib therapy? Leukemia Research, 32, 1636 1637.
12. Cazzola, M. Skoda, R. (2005) Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica, 90, 871 874.
13. Ceesay, M.M., Lea, N.C., Ingram, W., Westwood, N.B., Gaken, J., Mohamedali, A., Cervera, J., Germing, U., Gattermann, N., Giagounidis, A., Garcia-Casado, Z., Sanz, G. Mufti, G.J. (2006) The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia, 20, 2060 2061.
14. Cheng, D.S., Kushner, J.P. Wintrobe, M.M. (1979) Idiopathic refractory sideroblastic anaemia: incidence and risk factors for leukemic transformation. Cancer, 44, 724 731.
15. Cimino, J.J. Zhu, X. (2006) The practical impact of ontologies on biomedical informatics. Yearbook of Medical Informatics, 2006, 124 135.
16. Dameshek, W. (1965) Sideroblastic anaemia: is this a malignancy? British Journal of Haematology, 11, 52 58.
17. Dobo, I., Boiret, N., Lippert, E., Girodon, F., Mossuz, P., Donnard, M., Campos, L., Pineau, D., Bascans, E., Praloran, V. Hermouet, S. (2004) A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia. Haematologica, 89, 1207 1212.
18. Douglas, A.S. Dacie, J.V. (1953) The incidence and significance of iron-containing granules in human erythrocytes and their precursors. Journal of Clinical Pathology, 6, 307 313.
19. Epstein, E. Goedel, A. (1934) Haemmorhagische thrombocythamie bei vascularer schrumpfmilz. Virchows Archiv für Pathologische Anatomie und Physiologie und für klinische Medizin, Berlin, 292(2), 233 248.
20. Farr, W. (1856) Sixteenth Annual Report of the Registrar-General of England and Wales. Appendix pages 75-76. H.M. Stationery Office, London.
21. Gattermann, N., Aul, C. Schneider, W. (1990) Two types of acquired idiopathic sideroblastic anaemia (AISA). British Journal of Haematology, 74, 45 52.
22. Gattermann, N., Billiet, J., Kronenwett, R., Zipperer, E., Germing, U., Nollet, F., Criel, A. Selleslag, D. (2007) High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count >600 × 109/l) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood, 109, 1334 1335.
23. Germing, U., Strupp, C., Kundgen, A., Bowen, D., Aul, C., Haas, R. Gattermann, N. (2004) No increase in age-specific incidence of myelodysplastic syndromes. Haematologica, 89, 905 910.
24. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079 2088.
25. Grüneberg, H. (1941) Siderocytes in man. Nature, 148, 469 470.
26. Gupta, R., Abdalla, S.H. Bain, B.J. (1999) Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leukemia & Lymphoma, 34, 615 619.
27. Hamblin, T. (2009) Epidemiology of MDS. In : Myelodysplastic Syndromes: Pathobiology and Clinical Management, 2nd edn ed. by D.P. Steensma). Informa, New York, NY.
28. Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D., Wilkins, B.S., van der Walt, J.D., Reilly, J.T., Grigg, A.P., Revell, P., Woodcock, B.E. Green, A.R. (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. New England Journal of Medicine, 353, 33 45.
29. Jaffe, E.S., Harris, N.L., Stein, H. Vardiman, J.W. (eds 2001) WHO Classification: Tumours of Haematopoietic and Lymphoid Tissues. International Agency For Research on Cancer (IARC) Press, Lyon.
30. James, C., Ugo, V., Le Couedic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144 1148.
31. Juneja, S.K., Imbert, M., Sigaux, F., Jouault, H. Sultan, C. (1983) Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes. Journal of Clinical Pathology, 36, 566 569.
32. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779 1790.
33. Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. Deininger, M.W. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, 3377 3379.
34. Lossos, I.S., Czerwinski, D.K., Alizadeh, A.A., Wechser, M.A., Tibshirani, R., Botstein, D. Levy, R. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. New England Journal of Medicine, 350, 1828 1837.
35. Malcovati, L. Cazzola, M. (2008) Myelodysplastic/myeloproliferative disorders. Haematologica, 93, 4 6.
36. Nishii, K., Nanbu, R., Lorenzo, V.F., Monma, F., Kato, K., Ryuu, H. Katayama, N. (2007) Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature. Leukemia, 21, 1337 1338.
37. Orazi, A. Germing, U. (2008) The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia, 22, 1308 1319.
38. Orazi, A. Vardiman, J.W. (2009) Classification of myelodysplastic syndromes. In : Myelodysplastic Syndromes: Pathophysiology and Clinical Management, 2nd edn ed. by D.P. Steensma). Informa, New York, NY.
39. Palmer, S.R., Tefferi, A., Hanson, C.A. Steensma, D.P. (2008) Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. British Journal of Haematology, 140, 722 725.
40. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472 3476.
41. Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., Skoda, R. Cazzola, M. (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 111, 1686 1689.
42. Raza, A., Alvi, S., Borok, R.Z., Span, L., Parcharidou, A., Alston, D., Rifkin, S., Robin, E., Shah, R. Gregory, S.A. (1997) Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship. Leukemia & Lymphoma, 27, 111 118.
43. Remacha, A.F., Nomdedeu, J.F., Puget, G., Estivill, C., Sarda, M.P., Canals, C. Aventin, A. (2006) Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anaemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica, 91, 719 720.
44. Renneville, A., Quesnel, B., Charpentier, A., Terriou, L., Crinquette, A., Lai, J.L., Cossement, C., Lionne-Huyghe, P., Rose, C., Bauters, F. Preudhomme, C. (2006) High occurrence of JAK2 V617 mutation in refractory anaemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia, 20, 2067 2070.
45. Rosati, S., Mick, R., Xu, F., Stonys, E., Le Beau, M.M., Larson, R. Vardiman, J.W. (1996) Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome. Leukemia, 10, 20 26.
46. Rudzki, Z., Kawa, R., Okon, K., Szczygiel, E. Stachura, J. (2006) Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool. Virchows Archiv, 448, 59 67.
47. Schmitt-Graeff, A., Thiele, J., Zuk, I. Kvasnicka, H.M. (2002) Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. Haematologica, 87, 392 399.
48. Schmitt-Graeff, A.H., Teo, S.S., Olschewski, M., Schaub, F., Haxelmans, S., Kirn, A., Reinecke, P., Germing, U. Skoda, R.C. (2008) JAK2V617F mutation status identifies subtypes of refractory anaemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica, 93, 34 40.
49. Schnittger, S., de Sauvage, F.J., Le Paslier, D. Fonatsch, C. (1996) Refined chromosomal localization of the human thrombopoietin gene to 3q27-q28 and exclusion as the responsible gene for thrombocytosis in patients with rearrangements of 3q21 and 3q26. Leukemia, 10, 1891 1896.
50. Schnittger, S., Bacher, U., Haferlach, C., Dengler, R., Krober, A., Kern, W. Haferlach, T. (2008) Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anaemia with ringed sideroblasts and thrombocytosis. Leukemia, 22, 453 455.
51. Seri, M., Cusano, R., Gangarossa, S., Caridi, G., Bordo, D., Lo Nigro, C., Ghiggeri, G.M., Ravazzolo, R., Savino, M., Del Vecchio, M., d'Apolito, M., Iolascon, A., Zelante, L.L., Savoia, A., Balduini, C.L., Noris, P., Magrini, U., Belletti, S., Heath, K.E., Babcock, M., Glucksman, M.J., Aliprandis, E., Bizzaro, N., Desnick, R.J. Martignetti, J.A. (2000) Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nature Genetics, 26, 103 105.
52. Shaw, G.R. (2005) Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. British Journal of Haematology, 131, 180 184.
53. Spivak, J.L. Silver, R.T. (2008) The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood, 112, 231 239.
54. Steensma, D.P. (2006) JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. The Journal of Molecular Diagnostics, 8, 397 411 quiz 526.
55. Steensma, D.P. Tefferi, A. (2003) The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leukemia Research, 27, 95 120.
56. Steensma, D.P. Tefferi, A. (2008) JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood, 111, 1748.
57. Steensma, D.P., Dewald, G.W., Lasho, T.L., Powell, H.L., McClure, R.F., Levine, R.L., Gilliland, D.G. Tefferi, A. (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood, 106, 1207 1209.
58. Steensma, D.P., Caudill, J.S., Pardanani, A., McClure, R.F., Lasho, T.L. Tefferi, A. (2006) MPL W515 and JAK2 V617 mutation analysis in patients with refractory anaemia with ringed sideroblasts and an elevated platelet count. Haematologica, 91, ECR57.
59. Steensma, D.P., Hanson, C.A. Tefferi, A. (2008) Independent validation of the 2008 World Health Organization (WHO) reclassification of myelodysplastic syndromes (MDS) associated with ring sideroblasts. Blood (ASH Annual Meeting Abstracts 112, 928 Abstract 2686.
60. Streeter, R.R., Presant, C.A. Reinhard, E. (1977) Prognostic significance of thrombocytosis in idiopathic sideroblastic anaemia. Blood, 50, 427 432.
61. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E.D., Theil, K.S., Sekeres, M.A. Maciejewski, J.P. (2006) Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173 2181.
62. Tefferi, A. Vardiman, J.W. (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22, 14 22.
63. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092 1097.
64. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., Marfisi, R.M., Finazzi, G., Guerini, V., Fabris, F., Randi, M.L., De Stefano, V., Caberlon, S., Tafuri, A., Ruggeri, M., Specchia, G., Liso, V., Rossi, E., Pogliani, E., Gugliotta, L., Bosi, A. Barbui, T. (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110, 840 846.
65. Vardiman, J.W. (2006) Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology: American Society of Hematology. Education Program, 2006, 199 204.
66. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292 2302.
67. Wang, S.A., Hasserjian, R.P., Loew, J.M., Sechman, E.V., Jones, D., Hao, S., Liu, Q., Zhao, W., Mehdi, M., Galili, N., Woda, B. Raza, A. (2006) Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia, 20, 1641 1644.
68. Wang, Y.L., Vandris, K., Jones, A., Cross, N.C., Christos, P., Adriano, F. Silver, R.T. (2008) JAK2 mutations are present in all cases of polycythemia vera. Leukemia, 22, 1289.
69. Wardrop, D. (2008) Ockham's razor: sharpen or re-sheathe? Journal of the Royal Society of Medicine, 101, 50 51.
70. Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. Tefferi, A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81, 159 166.